Devatis Chairman & CEO Philipp Haas Highlights Long-Term Commitment to Switzerland in Medical Tribune Interview

Devatis’ Chairman & CEO, Philipp Haas, was featured in a comprehensive interview with Medical Tribune, a Swiss medical journal. In the interview, Mr. Haas shared insights into Devatis’ strategic vision, integrated business model, and long-term commitment to the Swiss healthcare market.

In the interview, Mr. Haas outlines the evolution of Devatis as a young yet firmly established pharmaceutical company, emphasizing its strong manufacturing backbone, vertically integrated supply chain, and focus on ensuring consistent quality and reliable availability of medicines. He also highlights Switzerland’s strategic importance for Devatis, along with the company’s growing local presence since entering the market in 2018.

The discussion further covers Devatis’ expanding portfolio in complex and clinically relevant therapeutic areas, including oncology, hematology, neurology, dermatology, rheumatology, and immunology, as well as the company’s approach to research, production, and regulatory standards under EU GMP, US FDA, and Swissmedic frameworks.

Reflecting on the future, Mr. Haas highlights Devatis’ focus on remaining a dependable, long-term partner for healthcare professionals by strengthening local teams, expanding the product portfolio, and maintaining full control over the value chain.

The full interview is available below.